PRAX – praxis precision medicines, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

PRAX

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

3/4

04:01 pm

prax

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Medium Report

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Report

2/25

06:24 am

prax

Praxis Precision Medicines (PRAX) was upgraded by Wolfe Research to "strong-buy".

Low Report

Praxis Precision Medicines (PRAX) was upgraded by Wolfe Research to "strong-buy".

Report

2/24

07:23 am

prax

A Look At Praxis Precision Medicines (PRAX) Valuation After Recent Share Price Momentum [Yahoo! Finance]

Low Report

A Look At Praxis Precision Medicines (PRAX) Valuation After Recent Share Price Momentum [Yahoo! Finance]

Report

2/23

06:01 pm

prax

Praxis Precision Medicines (NASDAQ:PRAX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.

Low Report

Praxis Precision Medicines (NASDAQ:PRAX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.

Report

2/20

10:33 am

prax

Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Truist Financial Corporation from $500.00 to $700.00. They now have a "buy" rating on the stock.

Low Report

Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Truist Financial Corporation from $500.00 to $700.00. They now have a "buy" rating on the stock.

Report

2/20

09:13 am

prax

Praxis Precision Medicines (NASDAQ:PRAX) was given a new $433.00 price target on by analysts at Robert W. Baird.

Low Report

Praxis Precision Medicines (NASDAQ:PRAX) was given a new $433.00 price target on by analysts at Robert W. Baird.

Report

2/20

08:28 am

prax

Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Wedbush from $95.00 to $130.00. They now have an "underperform" rating on the stock.

Low Report

Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Wedbush from $95.00 to $130.00. They now have an "underperform" rating on the stock.

Report

2/20

08:06 am

prax

Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.

Low Report

Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.

Report

2/20

08:02 am

prax

Praxis Precision Medicines (NASDAQ:PRAX) was given a new $305.00 price target on by analysts at Wells Fargo & Company.

Low Report

Praxis Precision Medicines (NASDAQ:PRAX) was given a new $305.00 price target on by analysts at Wells Fargo & Company.

Report

2/19

02:15 pm

prax

Praxis Precision Medicines Inc (PRAX) Q4 2025 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]

Low Report

Praxis Precision Medicines Inc (PRAX) Q4 2025 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]

Report

2/19

12:45 pm

prax

Praxis Precision Medicines Q4 Earnings Call Highlights [Yahoo! Finance]

Low Report

Praxis Precision Medicines Q4 Earnings Call Highlights [Yahoo! Finance]

Report

2/19

07:30 am

prax

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Low Report

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Report

2/19

03:53 am

prax

Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide [Yahoo! Finance]

Low Report

Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide [Yahoo! Finance]

Report

2/18

07:42 am

prax

Praxis Precision Medicines Inc (PRAX) Q4 2025 Earnings Report Preview: What To Look For [Yahoo! Finance]

Low Report

Praxis Precision Medicines Inc (PRAX) Q4 2025 Earnings Report Preview: What To Look For [Yahoo! Finance]

Report

2/16

12:38 pm

prax

Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX) [Yahoo! Finance]

Low Report

Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX) [Yahoo! Finance]

Report

2/13

07:02 pm

prax

Guggenheim Raises Target on Praxis Precision Medicines (PRAX) to $800 [Yahoo! Finance]

Low Report

Guggenheim Raises Target on Praxis Precision Medicines (PRAX) to $800 [Yahoo! Finance]

Report

2/10

07:14 am

prax

Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Guggenheim.

Low Report

Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Guggenheim.

Report

2/9

04:01 pm

prax

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

Low Report

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

Report

2/8

03:36 am

prax

A Look At Praxis Precision Medicines (PRAX) Valuation As Analysts Reaffirm Bullish CNS Pipeline Views [Yahoo! Finance]

Low Report

A Look At Praxis Precision Medicines (PRAX) Valuation As Analysts Reaffirm Bullish CNS Pipeline Views [Yahoo! Finance]

Report

2/4

04:01 pm

prax

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Low Report

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Report

2/4

08:03 am

prax

Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Needham & Company LLC from $460.00 to $510.00. They now have a "buy" rating on the stock.

Medium Report

Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Needham & Company LLC from $460.00 to $510.00. They now have a "buy" rating on the stock.

Report

2/2

10:26 am

prax

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders [Yahoo! Finance]

Low Report

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders [Yahoo! Finance]

Report

2/2

07:00 am

prax

Praxis Precision Medicines (NASDAQ:PRAX) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $282.00 price target on the stock.

Low Report

Praxis Precision Medicines (NASDAQ:PRAX) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $282.00 price target on the stock.

Report

1/30

07:17 am

prax

Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Low Report

Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Report

1/29

10:59 am

prax

Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at TD Cowen.

Low Report

Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at TD Cowen.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.